Gilead Sciences Inc. is seeking regulatory approval of its once-daily Truvada tablet as a way to prevent HIV.
The Foster City-based company (NASDAQ: GILD) said it submitted a supplemental application to the Food and Drug Administration. If successful, Gilead would be the first company to win FDA approval for a drug intended to prevent uninfected adults from getting infected with the AIDS virus, an approach known as pre-exposure prophylaxis, or PrEP.
But the move is controversial — even with some advocacy groups for AIDS patients — because opponents have said some gay men might engage in unprotected sex if they believe Truvada by itself protects them from getting the virus. Others have said that Truvada hasn’t proved that it can prevent transmission of HIV.
No comments:
Post a Comment